Skip to main content
. 2021 Sep 24;12:759267. doi: 10.3389/fphar.2021.759267

FIGURE 6.

FIGURE 6

IGF2BP2 knockdown decreases drug resistance of crizotinib-resistant NSCLC in vivo . (A) Tumor size. (B) Statistical analysis of tumor volume. (C) Statistical analysis of tumor weight. (D) H&E staining, IHC staining of Ki67 and Tunel assay in tumor tissues. **p < 0.01, ***p < 0.001 vs sh-NC group. Error bars represent SD. Data represent three independent experiments.